Insider Selling: Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Sells $388,864.07 in Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total value of $388,864.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Jeffrey Dierks also recently made the following trade(s):

• On Tuesday, October 29th, Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock. The stock was sold at an average price of $40.47, for a total value of $869,943.12.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY opened at $39.05 on Friday. The firm has a market cap of $2.23 billion, a P/E ratio of 18.51, a price-to-earnings-growth ratio of 0.49 and a beta of 0.78. The business’s 50 day moving average is $34.39 and its 200-day moving average is $34.88. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 1-year low of $28.14 and a 1-year high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company had revenue of $186.00 million during the quarter, compared to the consensus estimate of $184.07 million. During the same quarter last year, the firm earned $0.63 earnings per share. The company’s revenue was up 16.0% on a year-over-year basis. Equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Oppenheimer reissued an “outperform” rating and issued a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Cantor Fitzgerald boosted their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Needham & Company LLC reiterated a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research note on Monday, January 13th. Raymond James reissued an “outperform” rating and set a $40.00 price target on shares of Harmony Biosciences in a research report on Thursday, October 10th. Finally, Mizuho raised their price objective on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, October 10th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Harmony Biosciences currently has an average rating of “Buy” and a consensus price target of $55.00.

Institutional Trading of Harmony Biosciences

Institutional investors have recently bought and sold shares of the business. American Century Companies Inc. raised its position in shares of Harmony Biosciences by 53.7% in the second quarter. American Century Companies Inc. now owns 681,536 shares of the company’s stock valued at $20,562,000 after buying an additional 238,140 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Harmony Biosciences by 56.7% in the 2nd quarter. Renaissance Technologies LLC now owns 595,800 shares of the company’s stock valued at $17,975,000 after acquiring an additional 215,700 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Harmony Biosciences by 145.4% during the 2nd quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock valued at $9,220,000 after acquiring an additional 181,092 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in shares of Harmony Biosciences by 27.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock worth $26,416,000 after purchasing an additional 140,690 shares in the last quarter. Finally, HealthInvest Partners AB increased its position in shares of Harmony Biosciences by 335.2% in the third quarter. HealthInvest Partners AB now owns 151,875 shares of the company’s stock worth $6,075,000 after purchasing an additional 116,975 shares during the period. Institutional investors own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.